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Understanding service user and therapists’ experiences of incarcerated sex 
offenders receiving pharmacological treatment for sexual preoccupation 
and/or hypersexuality  
This research comprises two qualitative studies understanding the experiences of 1) 
convicted sex offenders voluntarily receiving pharmacological treatment to reduce 
sexual preoccupation and 2) therapists working with these offenders. The studies form 
part of a research programme evaluating the use of pharmacological treatment with 
sexual offenders. In study one, semi-structured interviews were conducted with 13 
sexual offenders receiving selective serotonin reuptake inhibitors (SSRIs). In study 
two, interviews were conducted with eight intervention staff with varying levels of 
experience of working with offenders taking anti-libidinals. Thematic analysis was 
used and in study one, two main themes emerged:  (i) the impact of the 
pharmacological treatment on prisoners’ daily functioning; (ii) barriers to 
compliance/engagement. In study two, three main themes emerged: (i) offenders’ 
reluctance to engage with pharmacological treatment; (ii) challenges for therapists; (iii) 
pharmacology: ‘just another piece of the puzzle’. Findings are discussed in relation to 
practice and future research. 
 
Keywords: sex offender; pharmacological treatment; qualitative; anti-libidinal; SSRI; 
hypersexuality 
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Introduction  
The presence of an excessive sexual appetite is referred to under a number of different labels 
within the literature. The term sexual preoccupation refers to ‘an abnormally intense interest 
in sex that dominates psychological functioning’ (Mann, Hanson & Thornton, 2010 p. 198), 
potentially resulting in engagement in a high frequency of sexual behaviours to relieve sexual 
urges. High frequency or excessive sexual behaviours is often referred to in the literature as 
hypersexuality (Kaplan & Krueger, 2010), hypersexual disorder (Krueger & Kaplan, 2002) 
and sexual addiction (Marshall, Marshall, Moulden & Serran, 2008). Sexual preoccupation is 
recognised as being a significant predictor for sexual, violent and general recidivism (Hanson 
& Morton-Bourgon, 2004; Hanson, Harris, Scott & Helmus, 2007). Potential explanations as 
to the link with sexual offending have been offered: ‘a general lack of self-control (common 
among young people and general criminals), specific problems controlling sexual impulses, 
and a tendency to overvalue sex in the pursuit of happiness’ (Hanson & Morton-Bourgon, 
2004, p.15). 
Psychological therapy exists as the preferred and accepted standard method of 
treatment for sexual offenders, with Sex Offender Treatment Programmes (SOTP) offered 
throughout prison and probation services within the UK (Ho & Ross, 2012). However, these 
programmes do not specifically target deviant sexual arousal and fantasies present in some 
sexual offenders (Adi et al., 2002) and so treatment needs relating to these may be left unmet. 
Similarly, for individuals who possess particularly dangerous deviant sexual interests, 
psychological treatment alone may not be sufficient (Marshall, Marshall & Serran, 2006). 
Furthermore, if sexual urges or thoughts are particularly intense, this can impact upon 
individuals’ ability to focus/participate in treatment programmes, and their ability to apply 
techniques to manage their sexual preoccupation (Marshall et al, 2006; Saleh, Grudzinskas, 
Malin & Dwyer, 2010). 
This treatment ‘gap’ has spawned the use of pharmacological interventions in the 
treatment of sexual offenders to diminish deviant sexual fantasies, urges and behaviours 
(Bourget & Bradford, 2008), and facilitate learning within psychological treatment 
programmes (Saleh et al., 2010). In 2007, protocols were established within the UK to allow 
the pharmacological treatment of sexual offenders (within the care of the prison or probation 
service) on a voluntary basis. This pharmacological treatment is viewed as a supplement and 
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‘needs to happen in combination with psychological treatment to help people understand their 
sexual thoughts and to challenge deviant thought processes’ (Home Office, 2007 p. 14). 
The pharmacological treatment, specifically anti-androgens (Cyproterone Acetate; 
CPA) and Selective Serotonin Reuptake Inhibitors (SSRIs; Fluoxetine) are the medications 
referred to in this research. CPA reduces sexual arousal through the reduction of testosterone 
levels (by approximately 30-40%, Bancroft, 1989) and SSRIs increase serotonin, which has 
been evidenced to inhibit sexual desire, psychological and physiological arousal and 
physiological orgasm (Jordan, Fromberger, Stolpmann, & Müller, 2011; Meston & Frohlich, 
2000). Research thus far has tentatively indicated positive results of both these treatments 
with sexual offenders, although the findings are currently considered inconclusive, and with 
further research needed (Beech & Mitchell, 2005; Grubin, 2007; Guay, 2009).  
The studies described here form part of a mixed-method programme of evaluation of 
the use of pharmacological treatment. Within the literature, there is an apparent lack of 
qualitative research which provides rich and in-depth understanding of this research topic. 
The aim of the current research is therefore to use qualitative methods to explore the impact 
of receiving pharmacological treatment from the perspective of both service users and of 
psychological intervention staff working with sexually preoccupied offenders. Qualitative 
methods have become a successful and accepted method of evaluation (McDavid, Huse & 
Hawthorn, 2005) and utilising qualitative methods within an evaluation is increasingly 
recognised for its ability to ‘tell the program’s story by capturing and communicating the 
participants stories’ (Patton, 2003, p. 2). It is hoped that this will add depth and understanding 
to the quantitative findings of the evaluation (Winder et al., under review).  
Method 
Context 
The current study is part of a mixed-method programme of research that was designed in 
collaboration with a UK sex offender prison to evaluate the use of pharmacological treatment 
to reduce sexual preoccupation and/or hypersexuality in sexual offenders. The establishment 
is the largest treatment centre for sexual offenders in Europe, housing approximately 840 
adult males who have been convicted of a sexual offence or who have a sexual element to 
their offending.  
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Participants  
Study one 
Participants comprised 13 convicted adult male sexual offenders prescribed SSRIs 
(Fluoxetine) to reduce their sexual preoccupation. Participants were White British (12) or 
White Other (1), with a mean age of 47 (29-72, s.d. = 13.7) and a mean IQ of 88 (59–108, s.d 
= 15.8). See table 1 for further participant information. Participant names were replaced with 
pseudonyms to maintain anonymity. 
 
Insert Table 1 
Study two 
Participants comprised eight members of psychological intervention staff working at a UK 
sex offender treatment prison. Participants were aware of offenders taking pharmacological 
treatment and were gained through purposive sampling. All participants worked within the 
psychology department (see table 2 for job titles, treatment and experience) and no specific 
training had been delivered to these participants on the pharmacological treatment. To 
maintain confidentiality, job titles are not assigned to individual participants, and names are 
replaced with non-gender specific pseudonyms.  
 
Insert Table 2 
Data Collection 
Ethical approval for both studies was received from HMPS and a UK University. Potential 
participants were identified by a prison-based gatekeeper for both studies (study one: the 
prescribing prison psychiatrist; study two: senior prison psychologist). For both studies, 
information about the research was distributed to all potential participants. Further 
information was presented at a face-to-face interview, in which written consent was obtained. 
British Psychological Society ethical guidelines were followed with regard to consent, 
opportunity for withdrawal of data, stated boundaries of confidentiality and debriefing of 
participants. All interviews took place in a dedicated private room within the prison. The 
interviews were digitally recorded, and transcribed verbatim.  
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Study one: Service users (convicted sexual offenders) 
Data was collected through semi-structured interviews (n = 22) with the lead author; 
interviews lasted between 25-135 minutes (mean = 75 minutes), with 1-3 interviews per 
participant. Where individuals were particularly high risk, interviews were conducted with 
two researchers present (n = 3).   
The interview schedule was developed through consultation with colleagues and 
structured into three broad sections; personal information and offending history; development 
of sexual preoccupation and use of the medication (SSRIs); other treatments (e.g. 
psychological) and future plans. 
Study two: Intervention staff  
Data was collected through semi-structured interviews with the second researcher; interviews 
lasted between 33-66 minutes (mean = 45 minutes), with one interview per participant. The 
interview schedule was developed as above and comprised five broad sections: referrals; 
consent; impact of medication; offenders’ views on medication; and offender rehabilitation.  
Analytic approach 
This research utilised thematic analysis as a method for ‘identifying, analysing and reporting 
patterns (themes) within data’ (Braun & Clarke, 2006, p. 79). The aim is to provide a 
complex, detailed and rich account of the data (Braun & Clarke, 2006). The researchers 
adopted techniques outlined by Miles and Huberman (1994) and Braun and Clarke (2006) 
entailing transcription, thorough reading to increase familiarisation and initial data reduction 
(coding). The data was organised systematically and themes were identified and reviewed. A 
type of inter-rater reliability was undertaken, with the analysis being ‘audited’ (Lincoln & 
Guba, 1985) by the co-authors to assess the validity of the interpretations.  
 
Study one: Results and discussion 
Two main themes were identified from the narratives provided by the service users. Each is 
discussed in depth (see table 3 for delineation of themes).  
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INSERT TABLE 3 
 
 
Superordinate theme 1: Impact of the pharmacological treatment on prisoners’ daily 
functioning 
Participants discussed a range of ways in which the medication had impacted upon their daily 
functioning; these included a reduction in sexual preoccupation, sexual arousal, and 
improvements in their abilities to manage negative emotions. 
Sub-theme 1.1: A clearer way of thinking: from sexually preoccupied to ‘human’  
Within the narratives, participants portrayed their situation prior to taking the medication: 
I think the best way of describing it is if a person has got a problem with their mind and 
it’s and it’s there constantly, 24 hours a day, 7 days … (Mohammed)1 
 
It's just getting the frustration out [masturbation], it's not that I want to have sex all the 
time it's just release. It's a relief, it just gets rid of that urge, know what I mean, out of 
your system and you feel alright and you can just get on with your daily routine (John) 
These accounts accentuate the difficulty and distress the participants are experiencing, with 
Mohammed’s extract highlighting the psychological aspects, the constant and intense sexual 
thoughts and fantasies. John describes a later stage where the thoughts have now become 
sexual urges and there is a compulsion to engage in sexual activity to relieve this urge. John 
suggests that a ‘daily routine’ or normality cannot commence until this urge has been 
relieved.  
When discussing the impact of the medication, all participants reported a reduction in 
sexual thoughts and fantasies in reports that it had ‘lessened them to almost nothing most of 
the time’ (Joshua).  However, participants acknowledge still having some sexual thoughts, as 
                                                 
1 All names provided in relation to the data are pseudonyms and are not related to actual participant names. 
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with Evan; he is aware that while the medication has repressed his sexual thoughts, fantasies 
and urges, they are still there and would return should the medication stop: ‘…it’s still there 
in a sense I’d say clawing at the cage wanting to be let out (Evan)’. 
Participants discussed the reduction in sexual thoughts and fantasies in relation to 
deviant content, which is reassuring considering the aim of pharmacological treatment is to 
reduce deviant sexual interests and behaviours while maintaining those that are appropriate 
(Bradford & Kaye, 1999; Bradford 2001). The Good Lives Model (GLM; Ward & Marshall, 
2004) of offender rehabilitation introduces the notion of primary human goods; actions, 
characteristics, experiences or states of mind that are intrinsically beneficial and are likely to 
increase psychological well-being if achieved. The central premise is that everybody 
(offenders and non-offenders) shares the same basic needs and are naturally predisposed to 
seek these goals or primary human goods. As such, offenders commit crime because as they 
are seeking these via inappropriate methods thus, rehabilitation is focussed on re-evaluating 
the goals and how these may be achieved. Considering this, reducing deviance sexual interest 
in individuals who have no appropriate alternative would be concerning, since according to 
the GLM, sexual satisfaction is a ‘primary human good’, thus eliminating capacity for sexual 
arousal and sexual outlets would be detrimental, reducing the individual’s level of well-being 
(Ward & Marshall, 2004). Circumstances such as this support the argument that 
psychological treatment is important alongside pharmacological treatment (Guay, 2009) to 
aid the development of healthy sexuality. 
Since receiving medication, participants report the current thoughts to be less intense 
and ‘a lot more manageable’ (Mohammed).  Additionally, participants report an increased 
ability to recognise inappropriate sexual thoughts and distract from them: 
I suppose it’s, it’s given me the opportunity and the and and the space in mind to address 
inappropriate fantasies and and slowly bring them into the, bring to something more 
acceptable …I mean it is just, it’s made me more able for me to ignore the inappropriate 
fantasies…yeah and then slowly given time and maybe because I’m ignoring them or 
because I’m not act acting on them they they’re not returning (Peter) 
This allows individuals to ‘choose’ the stimuli that they become aroused by and masturbate 
to. As Peter articulates, this process of ‘ignoring’ inappropriate fantasies has stopped them 
from returning, while masturbating to appropriate fantasies has reinforced these, thus altering 
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the nature of their fantasies: 
Erm it given me, erm it’s allowed me should I say to (3) develop my what are more 
appropriate sexual boundaries (Peter) 
Participants often attribute these changes in their arousal to the general reduction in sexual 
preoccupation and having more ‘head space’ to process thoughts and make conscious pro-
social decisions.  
Sub-theme 1.2: Reduced sexual arousal: a cost or benefit? 
The reduction in sexual thoughts and fantasies resulted in a reduction in sexual arousal and 
frequency of masturbation. The majority of participants also reported physical effects on 
arousal, including: an inability to achieve or maintain an erection: ‘I can get a bit of an 
erection but I can’t get a full erection’ (Tom); an inability to ejaculate or difficulty reaching 
ejaculation: ‘…it just goes on and on and on and I won’t ejaculate and I’ll just give up on it’ 
(Mohammed); and/or a reduction in the amount of semen if ejaculation occurred: ‘There was 
hardly anything there at all and sometimes there was nothing there at all…although I 
ejaculated er it was, I suppose you could call it a dry ejaculation’ (Neil). Previous research 
has also reported similar adverse effects of SSRIs (Strohm & Berner, 2001 as cited in Hill, 
Briken, Kraus, Strohm & Berner, 2003 p. 410).  Participant reactions to these effects varied 
across the sample: 
What you don’t have you don’t miss (Joshua) 
 
And at first, it was rather annoying erm, I also found that the fantasies that I had used 
previously, were no good any longer…Erm, they weren’t strong enough to tip me over 
the edge erm…and that became very difficult in trying to come up with a fantasy that 
was strong enough to enable me to ejaculate (Neil) 
Some participants appeared to accept such effects without compunction; others perceived 
these as problematic and attempted to counteract these by becoming non-compliant as a 
deliberate method of being able to achieve an erection, or by altering the nature of their 
fantasies.  Similar findings are documented that individuals may seek more sexually deviant 
fantasies in order to maintain sexual arousal or reach ejaculation and it is suggested that if 
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this occurs the dosage should be altered (Hill et al., 2003) and there should also be 
psychological intervention to dissuade individuals from adopting this strategy.  
Sub-theme 1.3: Managing negative emotions 
Participants reported an increased ability to manage their emotions in situations when 
previously they would become angry or frustrated. This is reiterated in descriptions of 
themselves as ‘more patient’ (Joshua), ‘more mellowed’ (Nathan) and ‘calm’ (Tom). One 
participant, Evan, attempts to offer an explanation: 
I think it’s, in a way, because my mind’s not so occupied with wrong thoughts that I’m 
able to recognise other thoughts coming in and feelings as well. So the fact that I know 
when I feel angry or I feel annoyed, I can think ‘yep, I am feeling that’ and then it’s kind 
of like ‘why?’ and then I think why I’m feeling like that. (Evan) 
Having more headspace appeared to allow participants to process thoughts and emotions that 
they previously could not, allowing them to respond differently. Participants who reported 
difficulties with depression also reported improvements from the medication, acknowledging 
its use for such conditions: ‘Cos it’s like an anti-depressant anyway’ (Nathan). This was 
something they spoke about very positively, with the reduction in depressive symptoms 
allowing them to be more sociable and feel less isolated. 
For some participants, these effects appear linked to those previously discussed, with 
masturbation providing an outlet to overcome depressive symptoms and ‘make me feel 
better’ (Nathan). This is supported within the sex offender literature (e.g. Cortoni & Marshall, 
2001; Mann, Hanson & Thornton, 2010; Seghorn & Ball, 2000) in which sexual outlets are 
recognised as ‘self medication’ or a coping strategy to overcome depression, anxiety or 
negative emotional states. Whether these effects of reduced depressive symptomology, and 
those of reduced arousal and preoccupation, are direct or indirect effects of the medication is 
currently unknown as there is difficulty in determining which is reduced first, but 
nevertheless a reduction in all was apparent. 
Superordinate theme 2: Barriers to compliance and engagement  
Generally the level of compliance appeared high, with individuals presenting as engaged and 
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motivated to take the (voluntary) medication. Nevertheless, some non-compliance was 
apparent and this theme considers the challenges that may impact upon compliance. 
Sub-theme 2.1: Participant concerns  
Participants experienced a number of concerns whilst taking the medication. Initially, these 
anxieties centred on the side effects of the medication: 
Erm I always do, I, any treatment we are doing or any medication I always, I suppose get 
worried about you know, side effects, you know, is it going to work? Is it going to make 
things worse? (Scott) 
Moreover, it was apparent that concerns arose from rumours circulating within the prison: 
‘they said you could get like 'man boobs' and things like that’ (Nathan). Although this is not 
necessarily wrong (gynecomastia or breast growth is a known side effect of anti-androgen 
treatment such as CPA – see Thibaut et al., 2010 - which is also prescribed within the prison), 
this was not applicable to participants in this study as they were taking SSRIs.  
Other concerns related to the impact the medication may have on future sexual 
relationships, particularly for individuals experiencing physical effects on arousal (discussed 
previously). Worries about becoming dependent on the medication, as well concerns that it 
may stop working as they are ‘getting used to it’ (Nathan) were also expressed.  
Although these apprehensions did not appear to have a deleterious effect on current 
compliance, some participants displayed uncertainty regarding their intentions to continue 
taking the medication after release, an uncertainty that can be attributed to some of these 
concerns: 
I'm not really sure. If it's going to help me most probably yeah, but I don't want to be 
independent on it, know what I mean?  I try not to be independent on tablets but if it's 
going to help me in the long run, then I er, I don't know.  I can't see no problem.  As long 
as I still have a healthy sexual relationship with a woman (John) 
This extract highlights the cost/benefit analysis that individuals may conduct, with a tension 
between the advantages of reducing inappropriate sexual thoughts/fantasies, contrasted 
against the possibility of impairing individuals’ ability to have a sexual relationship. While 
this may not be problematic in prison, it may create difficulties in trying to achieve a 
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meaningful intimate relationship when released.  
For all participants, gaining knowledge and information about the medication eased 
these concerns. Further, a good therapeutic relationship with the consulting psychiatrist 
appeared to be critical in providing participants with a safe environment to voice and discuss 
their concerns. 
Sub-theme 2.2: Not fully engaged  
Despite generally good levels of compliance, throughout the narratives there were instances 
in which participants exhibited a nonchalant attitude towards the medication: 
…because its not the really serious medication, it’s not cos I’ve got a heart defect or anything 
(Barry) 
 
when I remember to take them. I’m never very good at remembering tablets (Peter) 
Most participants reported occasionally forgetting to take their medication, and taking it as 
soon as they remembered; participants did not seem concerned about such lapses, believing 
the medication was ‘still in my system anyway’ (Joshua). However, periods of more 
sustained non-compliance (ranging from several days to over a week) were also self-reported 
by individuals. 
Individuals’ motivation apropos complying with pharmacological treatment is vital, 
when, as Harrison (2008 p. 2) points out, ‘treatment is in the pill form and administered by 
the offender’, emphasising the need for individuals to want to change and take medication to 
achieve this. Considering the uncertainty regarding compliance post-release voiced by some 
of our participants (see sub-theme 2.1), the importance of motivation and engagement 
becomes particularly vital when individuals are being released into the community; a less 
controlled environment, where the level of support for the medication is reduced and, as such, 
their motivation may wane.  
Sub-theme 2.3: Side effects of the medication 
The majority of participants (11/13) reported at least one side effect they associated with the 
medication, including: constipation, sweating, headaches, tiredness and/or nausea. In only a 
small number of cases did individuals find these unmanageable, with most participants 
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acknowledging that ‘they’ve gone within a couple a day or two so’ (Peter) or reporting they 
were ‘adjusting to the medication’ (Evan). This supports the literature regarding the transient 
nature of most side effects experienced with SSRIs (Bourget & Bradford, 2008). 
Additionally, some individuals reported developing techniques to manage these effects: ‘but 
err I take two at the moment err at night because if I take them during the daytime it tends to 
make me drowsy’ (Joshua).  
Study one: Conclusions 
Participants reported reduced levels of sexual preoccupation and/or hypersexuality, and it 
appears that the SSRIs were acting effectively as an anti-libidinal agent. There were some 
issues with offenders’ compliance and engagement on the medication, either as a result of 
side effects and/or the difficulties in achieving physical arousal. The latter is interesting in 
that individuals reported feeling happy about the reduction in sexual preoccupation (thinking 
about sex all the time), but less happy with the reduced capacity to perform the act of 
masturbation and ejaculation. Despite such issues, participants appear able to manage and 
overcome these challenges and compliance and engagement within this group seemed 
generally high. This may be a consequence of the medication being voluntary, ensuring that 
the individual is choosing to engage with the treatment and is motivated to reduce their 
sexual preoccupations and hypersexual behaviours. However, this level of compliance may 
not be demonstrated in circumstances in which the treatment is mandatory or motivation for 
the treatment may be different (to secure release). As such, developing our understanding of 
the factors that impact upon compliance will be important as decisions are made about these 
individuals regarding their level of risk, and subsequently movement through the prison 
system or release into the community. 
This treatment is by no means viewed as a cure and despite the improvements, 
participants demonstrate an understanding that if they stop taking the medication, without 
additional treatment, they would revert back to their situation prior to the medication. As 
such, all participants accentuated that the medication should not be seen as a replacement to 
psychological treatment and instead felt that they worked well together. Combining 
psychological treatment and SSRIs appears most effective, with the former offering insight 
and techniques to manage inappropriate sexual interests and the latter improving overall well-
being through the reduction of a range of symptoms, which in turn enhances the 
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implementation of psychological techniques. The increased effectiveness of this combination 
in comparison to mono-therapy, is supported in the literature (e.g. Saleh et al., 2010; Guay, 
2009). 
A number of limitations with this study are worth noting. First, as these findings are 
based purely on the self-report of offenders during interviews, the possibility that they were 
providing socially desirable responses must be considered. However, the voluntary nature of 
the treatment allows us to assume that participants would have little to gain from providing 
false effects of the medication to researchers. Further, lengthy interviews were conducted 
with all participants, typically with 1-2 follow-up interviews. This extended engagement 
provided the opportunity to build rapport and ‘improve the interviewer’s chances of 
overcoming potential social desirability biases and getting at the truth’ (Rubin 2000, p. 175). 
As with all qualitative research, this study presents a relatively small sample size and so the 
ability to generalise to wider populations is limited. However, despite the limitations, the 
authors consider that these findings inform our knowledge surrounding the use of effective 
medical treatment for sexual offenders and support the wider programme of evaluation.  
Finally, it should also be noted that a small number of our participants chose to stop 
taking the medication at some point in their treatment journey; however, without exception, 
all drop-outs subsequently asked to return to the medication. The complex treatment journeys 
of individuals referred for pharmacological treatment may inform our understanding of the 
role that sexual preoccupation plays in these individuals’ lives (see Winder, Lievesley, 
Elliott, Norman & Kaul, 2014, in press).  
Study two: Results and discussion  
Three main themes emerged from the analysis of therapist-participants’ narratives (see table 4 
for delineation of themes); each theme is discussed below.  
 
INSERT TABLE 4 
Superordinate theme 1: Offenders’ reluctance to engage with pharmacological 
treatment  
Participants reported offenders’ reluctance to taking the medication, highlighting concerns 
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about the impact and side effects, or a lack of awareness by offenders of their sexual 
preoccupation as a problem. 
Sub-theme 1.1: Offenders’ concerns about pharmacological treatment 
Therapist-participants provided consonant explanations for why offenders were reluctant to 
the medication: 
He seemed to think that once he started the medication that would be it for life but that 
would also then effectively chemically castrate him and he thought that that was 
permanent...because I think unfortunately it was a lot of rumours start flying around 
about the different medications. (Tony) 
 
When I did a referral a while ago, he really didn’t want to take the anti-libidinal2 
medication in compared to the SSRI because of the side effects of it. And he’d heard 
there were quite strong side effects and it had been bandied around about getting boobs 
and things and so he was really quite anxious about that. (Chris) 
 
They’re a bit dodgy about going on to the other one [anti-androgen] because they think 
they’re gunna lose their manlihood. (Charlie) 
These accounts highlight the challenges faced by treatment providers in encouraging suitable 
offenders to consider pharmacological treatment. Rumours circulate within any prison 
environment, and in this instance they serve to increase trepidation about taking the 
medication. Therapist-participants describe the concern around the side effects of the 
medication and also highlight offenders' fear of an inability to engage in sexual relationships 
indefinitely and ‘thinking that they’ll never be able to be aroused again’ (Ashley).  
Rumours arise in ambiguous situations and are used to restore a sense of control and 
reduce anxiety (Bordia & DiFonzo, 2004). Thus, there is a need for increased availability of 
information on the medication to reduce anxiety and the spreading and acceptance of false or 
exaggerated rumours. Nevertheless, it should be noted these rumours are not all false, as 
research indicates potential side effects of anti-androgen medication (including CPA) such as 
                                                 
2 Anti-libidinals is the term used by participants to describe anti-androgens (CPA). 
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gynecomastia (Bradford, 2001; Giltay & Gooren, 2009; Rainey & Harrison, 2008). However, 
this information should be readily available in appropriate format to educate offenders. In 
addition, offenders should be made aware of the long-term goal of the medication which is 
not to suppress all sexual drive and create an asexual individual, but to selectively suppress 
deviant sexual urges and fantasies (Thibaut et al., 2010). Informing offenders of all the 
possible implications and side effects should help instil confidence in the treatment and 
reduce the reluctance currently apparent in some offenders who may benefit from it.   
Sub-theme 1.2: Poor insight into the need for medication 
Therapists perceived that offenders' lack of insight into the problematic link between their 
level of sexual preoccupation and risk was another barrier to individuals taking the 
medication: 
He very much saw himself as actually being ok and not being a risk...Urm, so, as much 
as I tried to work with him to get him to see the benefits [of medication] he was quite 
reluctant. (Sam)  
 
In my opinion it would be maybe guys that are at later, through their sentence and have 
maybe done some group work because they’ll be more aware of what sexual 
preoccupation is and whether it’s a problem for them urm and I think until maybe they’re 
aware of that treatment need, they might not know, right this is a problem for me there’s 
something [medication] that can help me. (Alex) 
 
These accounts describe offenders who demonstrated a risk attributable to high levels of 
sexual preoccupation, but who may not consider taking medication, as they do not accept, or 
are unaware, that this is a risk factor for them. Alex explained that poor problem recognition 
and lack of awareness of the risks associated with sexually deviant thoughts are only likely to 
be addressed in group treatment. Consequently, until this point offenders may not consider 
medication as beneficial. As well as issues with problem recognition, many participants 
explained that offenders believe disclosing a need for pharmacological treatment increases 
their perceived risk level, increasing reluctance to do so: 
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A lot of them see that if they disclose high levels of preoccupation that actually that’s 
gunna actually make them feel more risky. (Jo)  
 
...those guys who aren’t really aware of the bigger picture, they might see that the parole 
board believes it to increase their risk by going on medication, because then they’re 
admitting to being riskier. (Tony)  
These extracts reflect the majority of participants' views that offenders believe admitting a 
need increases risk. Tony in particular referred to offenders who are not ‘aware of the bigger 
picture’, indicating their lack of insight is a causal factor here. 
It is widely accepted that poor problem recognition inhibits offenders' engagement 
and progress in therapy (Levenson, Macgowan, Morin & Cotter, 2009) and it is reasonable to 
apply this to pharmacological treatment. Perhaps more worrying is the indication that 
offenders are reluctant to disclose their sexual preoccupation due to fear of increasing their 
perceived riskiness. Burrowes and Needs’ (2009) Barriers to Change model describes the 
‘perceived cost benefit analysis of change’ (p. 45) as a potential barrier to treatment. This 
model would help to elucidate why some offenders may believe the costs of change outweigh 
the benefits, leading to low treatment readiness. Finally, participants revealed that many 
offenders were not even aware of the pharmacological treatment available: 
The amount of people that I’ve actually met and gone ‘do you know this [medication]’ 
and their like ‘no I've never heard of that before’ (Jo) 
 
So if you've got a prisoner here that’s got a high level of sexual preoccupation but he 
hasn’t done any group work and hasn’t really had any kind of time with urm psychology 
department then I'm doubtful they even are aware that it’s [medication] available. (Alex)  
 
But if they’re not open at that stage [induction interview], you know they might miss the 
opportunity you know through not knowing that it’s [pharmacology] available. (Billy) 
Jo highlighted experiences of meeting offenders who have never heard of the medication. 
Alex and Billy explained this lack of awareness may be due to information on the medication 
only being available at certain stages in a prison sentence.  
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This theme accentuates the importance of working with individuals to help them to 
recognise sexual preoccupation and take responsibility of their risk. Education with respect to 
both offenders and staff is required, so that sexual preoccupation and hypersexuality is 
recognised and acknowledged and treated as a positive step towards an individual taking 
responsibility for their risk.   
Superordinate theme 2: Challenges for therapists  
Participants expressed concern about lack of awareness regarding aspects of the 
pharmacological treatment process among themselves and those outside psychology and/or 
healthcare.  
Sub-theme 2.1: Lack of feedback about referrals  
Participants perceived the referral process as a one-way system, claiming that once they 
submitted a referral, they did not find out whether the offender started taking medication or 
not: 
So you really just feel like you’re just the messenger, and then you’re giving it [referral 
form] to them and they’ll do whatever they will with it. So, when you say ‘what do you 
hope to gain from it’, you don’t have the power to hope. (Charlie) 
 
...whilst the referrals come through psychology it almost feels like an outside process and 
not that much to do with us in some respects. (Ashley)  
These extracts represent the narrative of all participants; that referrals are an ‘outside 
process’. Charlie’s extract portrays a sense of feeling unjustly uninvolved in the referral 
process, indicated by the statement of being powerless. Ashley explains that the divide 
between departments in the prison hindered the process of gaining feedback on offenders' 
referrals.  
Participants were keen to communicate the benefits of getting feedback on the 
referrals they made: 
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If I was doing risk assessment or continuing to work with that person like in offender 
management or a probation officer I would suspect that they would want to know kind 
of, a regular kind of update, in terms of how the guy’s doing on the medication. (Chris) 
 
...if we know that they’re still getting them from healthcare, then that’s something. And 
that combined with their self-reports should give us more evidence to see, if they are 
taking them and it is working. (Alex) 
Chris’s extract captures the views of most participants, that awareness of who is on 
medication is important for all parties involved in an offender’s sentence plan. Alex also 
commented that feedback could increase the reliability of self-reports. Other benefits of 
feedback were identified as being a consequence of: (i) informing staff if a referral was ‘the 
right referral to make or did they not go on to have medication?’ (Chris); (ii) preventing 
therapists from a ‘false sense of security that this guy’s actually, somehow, maybe 
cognitively challenging his fantasies and his level of masturbation when actually it’s, it may 
be the medication that’s doing that’ (Jo); and (iii) ‘keeping them [prisoner] updated as to the 
stage they were at with the whole consent process and who’s looking at it, what it means, 
when the next time frame will be’ (Tony). Ashley provides a succinct summary of the 
benefits of improved communication and providing feedback to therapists stating it will 
promote ‘more of a, I suppose end-to-end offender management in a way because it’s more 
holistic.’  
This theme demonstrates participants desire to have more involvement in the 
pharmacology process, consistent with the aim of the National Offender Management Service 
(NOMS) Offender Management Model (OMM) (Grapes, 2006), to promote ‘a single, 
universal, core, end-to-end process which transcends the separate contributions of the main 
providers’ (p.12).  
 
Sub-theme 2.2: Being on the outside 
Participants discussed the lack of awareness and involvement in the pharmacology process 
among those outside of psychology: 
I think possibly it [referral form] could be promoted a bit more to staff. Because I think 
that people outside of psychology don’t have a lot of confidence in filling in that type of 
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stuff or feel that it’s just psychology’s job, when everyone’s involved in terms of risk and 
management. (Ashley) 
 
You might have a prisoner that comes to their personal officer, because they feel 
comfortable talking to that person and they [personal officer] might not really know a lot 
about it [medication]. And they might not have the confidence to put an application into 
psychology or go and speak to healthcare. (Alex) 
Ashley and Alex emphasised those outside psychology may lack confidence to complete 
referral forms and discussed a potential lack of awareness of responsibility to do so. This was 
supported by Chris who stated ‘officers on the wing particularly would just kind of think oh 
it’s [pharmacology] not my area and just dismiss it’. Most participants expressed that staff 
who do not have ‘that experience of dealing with guys who have intrusive thoughts’, ‘some 
more guidance would be useful’ (Jo). Furthermore, Alex highlights that it may be those 
outside psychology who offenders confide in. Thus, increased awareness in what sexual 
preoccupation is and how medication can help is important for all prison staff and is likely to 
increase staff taking responsibility for making referrals. 
Finally, an important extract from Jo’s data set indicates that ‘outsiders’ sometimes 
have unhelpful views about the pharmacology: 
...he said the last time he raised the medication in another jail that his probation officer 
told him that that would go against him at a parole board hearing. (Jo) 
Jo also stated that some prisoner officers feel medication is ‘just a way of cheating, you 
know, anyone can take medication’ but that ‘negative attitudes come from just lack of 
awareness’ (Jo). Although this view was only expressed by Jo, it is important to note, as it is 
another example of why increased knowledge about pharmacological treatment is important. 
This sub-theme has illustrated that staff outside of psychology may be unaware of the 
pharmacological referral process or the putative benefits of pharmacological treatment. 
However, it may be members of staff, such as wing officers, to whom offenders confide their 
sexual preoccupation. In addition, increased knowledge of the pharmacological methods 
available may help to reduce the rumours that circulate and cause concern among prisoners 
(see staff sub-theme 1.1). As the first point of call to a prison’s services and given their daily 
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contact with offenders, prison officers may play a crucial role in the pharmacological referral 
process (Crewe, 2011).  
This theme suggests a programme of education and training is needed with those 
outside psychology in the types of behaviours that may indicate a need for medication. The 
referral loop should also be examined and moved to a two-way system where each referral, 
irrespective of the outcome, results in feedback being provided to the original referrer, as well 
as those involved in the offender’s treatment and supervision.  
Superordinate theme 3: Pharmacology: ‘just another piece of the puzzle’  
All therapist-participants expressed positive attitudes towards pharmacological treatment; 
they emphasised the fact that the medication should not be viewed as a ‘cure’ or something 
that can work alone, but rather it was ‘just another piece of the puzzle really to kind of help 
the guys make some of the changes that they need to’ (Tony). 
Sub-theme 3.1: Psychology and pharmacology working together 
All therapist-participants promulgated pharmacological treatment in conjunction with 
psychological treatment:  
But it [medication] needs to be ran alongside something else. In the same way that I'm 
running a really good programme with the guy but without the medication it’s not going 
to be beneficial. (Charlie) 
 
I don’t think it [medication] should ever be used as a standalone because I don’t think 
that it is the cure as I’ve said. And I don’t think that should ever be the intention behind 
the medication because ultimately they can stop taking it at any point and so therefore 
they’re kind of left with nothing. (Chris) 
These extracts reflect the consistent view among participants that psychological work 
alongside pharmacology is extremely important because, without psychological treatment, 
offenders could stop taking the medication at any time and be left with no other strategies to 
stop their offence related thoughts and desires. Sam reported the experience of an offender 
who ‘was still having a lot of sexual thoughts every day’ but ‘found it harder to ejaculate’. 
Sam went on to explain that ‘he hadn’t done much treatment so he wasn’t very 
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knowledgeable so he basically expanded his sexual thoughts to become more graphic, to 
allow him to ejaculate’. Sam’s extract as well as findings from study one highlight how 
delayed ejaculation can lead to offenders resorting to changing unhealthy fantasies in order to 
reach orgasm.  
The increased effectiveness of combining psychological work and pharmacology in 
the treatment of sexual offenders is widely accepted (Guay, 2009; Hall & Hall, 2007; Krauss 
et al., 2006; Mann & Marshall, 2009). Gordon and Grubin (2004) assert that there are high 
dropout rates with pharmacological treatment, and therefore medication should almost always 
be combined with psychological interventions.  
Sub-theme 3.2: Importance of throughcare 
The notion of throughcare, to provide continuous care or treatment post-release, was also 
highlighted by the majority (6/8) of participants as being important, claiming that 
pharmacology is ‘a really good idea but the throughcare is also really important too’ (Ashley) 
because ‘it [medication] needs to be followed up in the community as well’ (Billy): 
It’s about not just communicating with us, but making that link with the offender 
manager, and ensuring that he’s got a doctor that continues to prescribe it out there and 
all of that will need to be in place. I think it’s really important because that’s where his 
de-stabilizers are gunna be, that’s where his triggers are gunna be, more so. (Charlie) 
Charlie explained that ensuring support is available to promote the continuation of 
medication on release is vital due to the change in environment increasing offenders' risk. 
Others emphasised the importance of offenders taking responsibility, to ensure continuation 
into the community: 
Managing their sexual thoughts is their responsibility. I'm only giving them tools to do 
that and once I've gone, its gunna be up to them or once their released its gunna be up to 
them so really, I try and get across the responsibility is pretty much all them. (Sam) 
 
It's gunna be their responsibility to manage it [medication] in the community. It’s their 
responsibility to manage all of their risk, not just around sexual preoccupation. (Alex) 
The above narratives place emphasis on ‘them managing themselves’ (Alex), highlighting the 
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importance of offenders taking responsibility for their medication as ‘there is no control, 
particularly in the out like in the community’ and ‘so there is no point in forcing somebody 
into doing it because it’s not gunna have a long lasting effect’ (Chris). However, Charlie 
explained that often motivation to continue medication declines on release: 
Sometimes they are less inclined to take it when they are released because they think 
they are ok and oh parole board have said I’m fine to go out, I don’t need anything. 
(Charlie) 
Charlie described a classic misconception of patients taking medications; when it works 
patients often stop taking the medication (O’Donhue & Levensky, 2006). Reduced 
motivation on release is a recognised concept and accentuates the importance in ensuring 
those involved in care in the community are aware of the potential need to re-engage 
offenders in treatment, even when motivation in prison was high (Barrett, Wilson & Long, 
2003). This is particularly the case as the association between motivation and increased 
responsibility to change is an established phenomenon within sexual offender treatment 
(Garland & Dougher, 1991; Tierney & McCabe, 2002).  
Participants also commented on other difficulties faced with the medication during 
throughcare: 
...he was released to an area where there wasn’t a psychiatrist that was sort of on board 
with the process...I think he went out with a week's worth of medication. (Sam) 
 
When it’s difficult to chase that information [regarding who is on medication] we’re not 
then able to share it with the people who are going to be managing them in the 
community...and they are the people who need to know really when they’re getting 
released. (Ashley) 
These extracts demonstrate gaps in the current throughcare process. In particular, Sam’s 
narrative raises the concern that continuing medication in the community can be subject to 
the attitudes of GPs and this may cause additional challenges for individuals. This highlights 
the need for more support and collaboration to promote the throughcare of medication, 
particularly as stimuli associated with risk and re-offending are intensified in the community 
(Lussier, Dahabieh, Deslauriers-Varin & Thomson, 2011). To provide this support, staff 
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involved must be informed who is on medication, reinforcing the data within the sub-theme 
2.1.  
Sub-theme 3.3: Therapists’ recognising where medication will help  
Staff reported relying heavily on offenders’ self-reports to identify who needed medication. 
Ashley provided a range of reasons for referral which reflected the views of all participants: 
(i) ‘if they were reporting a level of sexual thoughts that was unhelpful for them’; (ii) ‘if they 
are reporting what appears to be a high level of sexual preoccupation in custody like 
masturbating several times a day’; (iii) if ‘they’re reporting offence related thoughts’; and (iv) 
‘if they’re saying things like they can’t focus on education because of the level of these 
thoughts’. Other participants explained offenders may disclose that their sexual arousal is 
‘uncontrollable’, for example, reporting they are ‘becoming aroused when they don’t want to’ 
(Sam).  
Participants also discussed why they would not refer individuals for medication: (i) if 
an offender has ‘got a number of strategies they can use’, (ii) ‘if they've used distraction as a 
technique, if that’s been successful for them’ (Ashley), (iii) ‘if they are telling me that they 
are managing whatever it is that might be happening whatever the sexual thoughts about… 
with techniques of some description’ (Sam). Ashley also highlighted that deciding not to refer 
‘relies on self-report largely’. However, there was an agreement among most therapist-
participants that they would rather refer than not: 
But I would never just diss...if I thought that somebody would benefit from it I wouldn’t 
just dismiss that and not refer them. (Chris) 
This sub-theme illustrates how heavily staff rely on offenders’ self-reports to recognise a 
need for medication. This simply reinforces the conclusions thus far; that all staff must be 
involved in the referral of medication to ensure that any offender who discloses a need is 
followed up and addressed. This sub-theme also illustrates participants’ reasons for referral, 
all of which are in line with Guay’s (2009) recommendations for characteristics and 
behaviours which indicate pharmacological treatment would be suitable. Moreover, 
participants’ preference to refer rather than not demonstrates an inclusive approach for all 
offenders who may need medication.  
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Study two: Conclusions 
This research highlights areas for improvement as well as of good practice with the 
pharmacological treatment in this study. An increased knowledge of the medication, both for 
offenders and staff outside of psychology and healthcare is essential, in order to reduce 
uninformed decisions by offenders and increase awareness and confidence to refer among 
staff. As a general rule, institutions provide inductions to groups of staff when new 
programmes are introduced, however this research indicates that this alone is not sufficient. 
Specific training is necessary to educate those staff who are not initially involved in the 
development of a treatment. This should focus on: the pharmacological procedures (including 
referrals and long terms goals of the treatment); the effects and side effects of medication; 
behaviours/self-reports indicative of a need for medication; and emphasising the importance 
of all staffs' responsibility to refer. Participants (who work within psychology) displayed 
good ability in the referral process. However, if the need for medication can be established 
earlier in an offender’s sentence, this will encourage the individual to address their risk and 
possibly improve the effectiveness of psychological programmes by reducing sexual 
preoccupation and increasing the offender’s ability to focus on treatment.  
One of the most consistent concepts within the data set was the emphasis on the 
medication not being used alone. Participants felt strongly about this, reflected in their 
frequent discussion of the need for psychological work alongside. In addition, the importance 
of support into the community was accentuated by most, highlighting the need for the 
throughcare process to be carefully and appropriately tailored for offenders taking 
medication. The desire for feedback about referrals was also a prevailing topic across 
participants, with many benefits cited, and is therefore highlighted as an essential area for 
improvement (although confidentiality must be considered).  
A limitation of this study worth noting is that participants did not always have 
detailed insight into all the areas probed by the interview schedule, due to their differing roles 
and experiences. However, the data provided a rich overall perspective of the 
pharmacological procedures, allowing recommendations to be made for the institution, some 
of which are already being applied.  For example, training days for staff both in and out of 
psychology (e.g. wing staff, Offender Management Unit staff) have already been completed 
following this research. There is also the potential limitation of respondent bias due to social 
desirability (Rubin, 2000), particularly as the participants were staff. However, during 
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interviews, participants appeared open in their responses and discussed freely their lack of 
knowledge in certain areas of enquiry. Moreover, where applicable, findings were consistent 
with offenders’ perspectives (see study one).  
To conclude, the findings of this research depict that adopting a multidisciplinary 
approach to the pharmacological intervention, where information sharing and collaboration 
are frequent, will encourage end-to-end offender management. This will contribute to a more 
successful delivery of the pharmacological treatment, which adheres to NOMS business 
objectives of crime reduction, public protection and offender reform (Turley, Ludford, 
Callanan & Barnard, 2011).  
General conclusions 
 The studies presented here are part of a comprehensive mixed-method programme of 
research to evaluate pharmacological treatment with sexually preoccupied sexual offenders in 
custody. The qualitative studies presented in this paper add an additional dimension to the 
quantitative research evaluating the effectiveness of the pharmacological treatment in that it 
allows for an exploration of personal experiences, both from the perspective of offenders 
taking the medication, and (in study two), a better understanding of the views of therapists 
working with sexually preoccupied sex offenders.  
Findings from study one demonstrate that offenders did not view medication as a 
‘cure’ and understood that if they stopped taking the medication, they would revert back to 
their previous states of sexual preoccupation. This corroborates with therapist-participants’ 
views in study two. Both sets of participants asserted their beliefs that pharmacological 
treatment would not work as a replacement for psychological treatment, with the latter giving 
individuals skills and tools to manage their risk generally. This finding is also supported by 
literature (Guay 2009; Thibaut et al., 2010.). Importantly, findings from both study one and 
two supported each other in terms of effects of the medication in reducing sexual 
preoccupation (Lievesley et al., 2012). 
Whilst it is fair to claim that qualitative research can make only a limited contribution 
to studies evaluating the effectiveness of interventions per se, the authors consider that such 
methods can have a substantive role in contributing to understanding the effectiveness of 
interventions more generally. The rich data derived from this type of research can help us to 
understand the context and individuals that comprise an important part of the evaluation, 
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revealing, in this instance: the need for further education of prison staff and offenders 
apropos the medication; a change in the referrals process such that a feedback loop is set up 
for all referrals; and further research exploring factors affecting compliance and engagement. 
These studies have contributed to our knowledge around the use of pharmacological 
treatment for sexually preoccupied sexual offenders in custody, offering a more holistic 
understanding of the effectiveness of this medication, and the diverse factors that might 
facilitate or impede its utility. 
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Table 1: Participant Information (Study 1) 
 
 
Participant Marital 
Status 
Index offence(s) Previous non-
contact sexual 
offences? 
Previous 
contact sexual 
offences? 
Fluoxetine 
dose 
Length of 
time on 
medication  
1 
 
 
 
Single 
 
 
 
Rape (child) x 3 
Attempted buggery x 2 
Rape (adult) x 2 
Indecent assault (child) x 3 
Yes 
 
 
 
Yes 
 
 
 
20mg 
 
 
 
4 months 
 
 
 
2 Divorced Rape (adult) x 2 No Yes 20mg 7 months 
3 Single Sexual assault (child) No Yes 20mg 3 months 
4 Single Sexual activity with a child No Yes 20mg 11 months 
5 Single Possessing indecent images Yes Yes 40mg 9 months 
6 
 
Single 
 
 Murder 
Indecent exposure x 5 
Yes 
 
No 
 
20mg 
 
7 months 
 
7 Divorced Indecent assault (child) Yes Yes 40mg 19 months 
8 Single Sexual assault (child) No Yes 20mg 9 months 
9 
 
 
Divorced 
 
 
Sexual assault (child) x 2 
Rape (child) x 12  
Sexual activity with a child 
No 
 
 
No 
 
 
20mg 
 
 
6 months 
 
 
10 Single  Murder No No 20mg 5 months 
11 Single Sexual activity with a child No Yes 40mg 11 months 
12 
 
Single 
 
Indecent assault (child) x 5  
Buggery 
No 
 
Yes 
 
40mg 
 
18 months 
 
13 Divorced Rape (child) No Yes 20mg 3 weeks 
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Table 2: Participant Information (Study 2) 
 
 
 
Key: 
HSF = Healthy Sexual Functioning 
SOTP = Sexual Offender Treatment Programme 
Job titles of participants:  Chartered forensic psychologist; Group work facilitator; Psychology assistant; and Forensic 
psychologist in training 
Participant 
 
Style of Treatment 
Delivered 
Type of Treatment 
Delivered 
No. of Referrals No. of offenders  worked with 
on anti-libidinals  
Charlie One-to-One HSF 3+ 3+ 
Tony Group Living Skills Programme 1-3 1-3 
Ashley Neither N/A 0 1-3 
Chris Both SOTP & HSF 3+ 1-3 
Sam Both SOTP & HSF 1-3 1-3 
Billy Group SOTP 1-3 1-3 
Alex Group SOTP 0 1-3 
Jo Group SOTP 3+ 3+ 
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Table 3: Superordinate and sub-themes (Study 1) 
 
Superordinate Themes Sub-themes 
 
Impact of the pharmacological treatment on 
prisoners’ daily functioning 
 
A clearer way of thinking: from sexually 
preoccupied to ‘human’ 
Reduced sexual arousal: a cost or benefit? 
Managing negative emotions 
 
Barriers to compliance and engagement 
 
Participant concerns 
Not fully engaged 
Side effects of the medication 
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Table 4: Superordinate and sub-themes (Study 2) 
Superordinate Themes Sub-themes 
Offenders’ reluctance to engage with 
pharmacological treatment 
Offenders’ concerns about pharmacological 
treatment 
Poor insight into the need for medication 
Challenges for therapists 
Lack of feedback about referrals 
Being on the outside 
 
Pharmacology: ‘just another piece of the puzzle’ 
Psychology and pharmacology working together 
Importance of throughcare 
Therapists’ recognising where medication will help 
 
 
